Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

Subjects:

Time course of best-corrected visual acuity (BCVA) in all eyes. by Yasuyuki Sotani (20114144)

Subjects:

Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

Subjects:

Time course of central retinal thickness (CRT) in all eyes. by Yasuyuki Sotani (20114144)

Subjects:

Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

Subjects:

Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

Subjects:

Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

Subjects:

Preoperative background characteristics of the patients. by Yasuyuki Sotani (20114144)

Subjects:

Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection. by Ryan J. Treves (13527735)

Effects of GJE extract treatment decreased expression of NF-kB p65. by Natnicha Suttawong (22367172)

The reduced virulence of Δalta1 mutants is not primarily due to a decrease in growth. by Shuhuan Zhang (748003)

Mean lipid profile (mmol/L) upon completion of the experimental period. by Elsie D. Oduor (22521785)

Decreased clonogenic capacity of U87MG and U251MG GB cells following treatment with SHG-44 and cis-platin at equal concentrations. by Denis Mustafov (19137870)

“…<b>(D)</b> Similarly, U251MG cells showed significantly decreased clonogenic potential upon 100ΜM SHG-44 treatment when compared to 100ΜM cis-platin and the untreated control. …”

Effect of different doses of the defatted extract (DE) of the leaves of <i>S. malaccense</i> and <i>S. samarangense</i> on urea and creatinine levels. Data represented as mean±SEM... by Fatma A. Moharram (9276104)

Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2018 ^a indicates ≥1.50 SD (17.9) from the mean (32.9... by Luke R. Cavanah (19022435)

Large state-wide variation (11.1-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2015 ^a indicates ≥1.50 SD (20.2) from the mean (36.... by Luke R. Cavanah (19022435)

Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2017 ^a indicates ≥1.50 SD (18.0) from the mean (33.1... by Luke R. Cavanah (19022435)

Large state-wide variation (8.5-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2019 ^a indicates ≥1.50 SD (16.8) from the mean (31.0... by Luke R. Cavanah (19022435)

Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2020 ^a indicates ≥1.50 SD (16.0) from the mean (29.9... by Luke R. Cavanah (19022435)

Large state-wide variation (10.2-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2016 ^a indicates ≥1.50 SD (19.2) from the mean (34.... by Luke R. Cavanah (19022435)